On the public citation graph
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy
0 signed · 123 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1007/978-3-540-70617-5_11openalex-snapshot
Measles Virus for Cancer Therapy
inferredcites →https://doi.org/10.1007/s10238-005-0076-1openalex-snapshot
The Coxsackie-adenovirus receptor has elevated expression in human breast cancer
inferredcites →https://doi.org/10.1016/j.ymthe.2006.05.008openalex-snapshot
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF
inferredcites →https://doi.org/10.1016/s1535-6108(03)00241-1openalex-snapshot
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
inferredcites →https://doi.org/10.1038/gt.2008.58openalex-snapshot
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma
inferredcites →https://doi.org/10.1038/gt.2009.29openalex-snapshot
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity
inferredcites →https://doi.org/10.1038/gt.2011.37openalex-snapshot
Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα
inferredcites →https://doi.org/10.1038/mt.2009.318openalex-snapshot
Enhancing the Therapeutic Effect Against Ovarian Cancer Through a Combination of Viral Oncolysis and Antigen-specific Immunotherapy
inferredcites →https://doi.org/10.1038/mt.2013.249openalex-snapshot
Maraba Virus as a Potent Oncolytic Vaccine Vector
inferredcites →https://doi.org/10.1038/mt.2014.118openalex-snapshot
Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus
inferredcites →https://doi.org/10.1038/mt.2014.134openalex-snapshot
The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site
inferredcites →https://doi.org/10.1038/mt.2014.160openalex-snapshot
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
inferredcites →https://doi.org/10.1038/mt.2015.156openalex-snapshot
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
inferredcites →https://doi.org/10.1038/mto.2014.6openalex-snapshot
Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy
inferredcites →https://doi.org/10.1038/nature13904openalex-snapshot
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
inferredcites →https://doi.org/10.1038/nature13954openalex-snapshot
PD-1 blockade induces responses by inhibiting adaptive immune resistance
inferredcites →https://doi.org/10.1038/nbt.2157openalex-snapshot
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma
inferredcites →https://doi.org/10.1038/nm.2390openalex-snapshot
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors
inferredcites →https://doi.org/10.1038/nm.3089openalex-snapshot
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
inferredcites →https://doi.org/10.1038/nm730openalex-snapshot
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
inferredcites →https://doi.org/10.1038/nrd4663openalex-snapshot
Oncolytic viruses: a new class of immunotherapy drugs
inferredcites →https://doi.org/10.1038/sj.gt.3303098openalex-snapshot
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors
inferredcites →https://doi.org/10.1056/nejmoa1200694openalex-snapshot
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
inferredcites →https://doi.org/10.1056/nejmoa1504030openalex-snapshot
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1093/neuonc/nov173openalex-snapshot
Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling
inferredcites →https://doi.org/10.1111/j.1600-065x.2010.00923.xopenalex-snapshot
The PD‐1 pathway in tolerance and autoimmunity
inferredcites →https://doi.org/10.1126/science.282.5392.1332openalex-snapshot
Reovirus Therapy of Tumors with Activated Ras Pathway
inferredcites →https://doi.org/10.1126/scitranslmed.3003578openalex-snapshot
Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients
inferredcites →https://doi.org/10.1126/scitranslmed.3008095openalex-snapshot
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
inferredcites →https://doi.org/10.1128/jvi.76.2.895-904.2002openalex-snapshot
Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant Disease
inferredcites →https://doi.org/10.1158/0008-5472.can-09-3567openalex-snapshot
Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients
inferredcites →https://doi.org/10.1158/0008-5472.can-11-2975openalex-snapshot
Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus
inferredcites →https://doi.org/10.1158/0008-5472.can-11-3001openalex-snapshot
Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
inferredcites →https://doi.org/10.1158/0008-5472.can-13-2564openalex-snapshot
Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody
inferredcites →https://doi.org/10.1158/1078-0432.ccr-07-1510openalex-snapshot
Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus
inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-0524openalex-snapshot
A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-0831openalex-snapshot
Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity
inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-0334openalex-snapshot
Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-2181openalex-snapshot
Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-0979openalex-snapshot
A Novel Therapeutic Regimen to Eradicate Established Solid Tumors with an Effective Induction of Tumor-Specific Immunity
inferredcites →https://doi.org/10.1158/2326-6066.cir-14-0015openalex-snapshot
Oncolytic Viruses and Their Application to Cancer Immunotherapy
inferredcites →https://doi.org/10.1159/000455014openalex-snapshot
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
inferredcites →https://doi.org/10.1172/jci41431openalex-snapshot
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice
inferredcites →https://doi.org/10.1200/jco.2014.58.3377openalex-snapshot
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
inferredcites →https://doi.org/10.4161/onci.26013openalex-snapshot
Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+T-cell responses to anticancer vaccines
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4652904openalex-extracted
A Dual-Functional Oncolytic Adenovirus Armed with Pd-L1 Inhibitor Potentiates its Antitumor Activity
inferred← citeshttps://doi.org/10.1002/mco2.70725openalex-snapshot
Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-28891-4_5openalex-snapshot
Regional Gene Therapy for Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-50287-4_27openalex-snapshot
Oncolytic Viruses as Immunotherapeutic Agents
inferred← citeshttps://doi.org/10.1007/s00262-020-02774-7openalex-snapshot
Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma
inferred← citeshttps://doi.org/10.1007/s00262-021-02946-zopenalex-snapshot
Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model
inferred← citeshttps://doi.org/10.1007/s00262-023-03509-0openalex-snapshot
Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer
inferred← citeshttps://doi.org/10.1007/s11864-024-01211-6openalex-snapshot
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas
inferred← citeshttps://doi.org/10.1007/s12032-025-02939-3openalex-snapshot
Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy
inferred← citeshttps://doi.org/10.1007/s40257-016-0238-9openalex-snapshot
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
inferred← citeshttps://doi.org/10.1016/b978-0-12-823397-9.00012-0openalex-snapshot
Oncolytic viruses in immunotherapy
inferred← citeshttps://doi.org/10.1016/bs.acr.2026.02.004openalex-snapshot
Vesicular stomatitis virus (VSV) as an oncolytic therapeutic agent for cancer
inferred← citeshttps://doi.org/10.1016/bs.pmbts.2019.06.015openalex-snapshot
Synergistic combination of oncolytic virotherapy with CAR T-cell therapy
inferred← citeshttps://doi.org/10.1016/j.cytogfr.2018.03.006openalex-snapshot
Armed oncolytic viruses: A kick-start for anti-tumor immunity
inferred← citeshttps://doi.org/10.1016/j.cytogfr.2020.10.007openalex-snapshot
Cytokines in oncolytic virotherapy
inferred← citeshttps://doi.org/10.1016/j.imbio.2019.11.010openalex-snapshot
Promising approaches in cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.intimp.2024.111579openalex-snapshot
A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity
inferred← citeshttps://doi.org/10.1016/j.lfs.2025.123489openalex-snapshot
Mesenchymal stem cell-derived small extracellular vesicles as a delivery vehicle of oncolytic reovirus
inferred← citeshttps://doi.org/10.1016/j.omtm.2020.01.001openalex-snapshot
Oncolytic Viruses and the Immune System: The Dynamic Duo
inferred← citeshttps://doi.org/10.1016/j.omto.2019.04.003openalex-snapshot
Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
inferred← citeshttps://doi.org/10.1016/j.semcancer.2018.06.006openalex-snapshot
Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis
inferred← citeshttps://doi.org/10.1016/j.semcancer.2021.05.019openalex-snapshot
Optimal timing of PD-1 blockade in combination with oncolytic virus therapy
inferred← citeshttps://doi.org/10.1016/j.seminoncol.2026.152564openalex-snapshot
Microbiome oncolytic virus interactions in cancer: emerging evidence and therapeutic implications for immunotherapy
inferred← citeshttps://doi.org/10.1016/j.smim.2025.101994openalex-snapshot
Oncolytic virotherapy: Sparking durable anti-tumor immunity through microenvironment modulation
inferred← citeshttps://doi.org/10.1016/j.smim.2025.101995openalex-snapshot
Reovirus oncolysis and the next frontiers for this unique oncoviral immunotherapy
inferred← citeshttps://doi.org/10.1016/j.smim.2026.102033openalex-snapshot
Dendritic cells as central coordinators of oncolytic virus-induced antitumor immunity
inferred← citeshttps://doi.org/10.1016/j.ymthe.2018.04.001openalex-snapshot
Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones
inferred← citeshttps://doi.org/10.1016/j.ymthe.2019.07.019openalex-snapshot
Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC
inferred← citeshttps://doi.org/10.1038/s41417-018-0018-1openalex-snapshot
Recombinant viruses with other anti-cancer therapeutics: a step towards advancement of oncolytic virotherapy
inferred← citeshttps://doi.org/10.1038/s41417-021-00389-3openalex-snapshot
Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model
inferred← citeshttps://doi.org/10.1038/s41467-018-07344-1openalex-snapshot
PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance
inferred← citeshttps://doi.org/10.1038/s41467-021-22115-1openalex-snapshot
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
inferred← citeshttps://doi.org/10.1038/s41568-018-0009-4openalex-snapshot
Oncolytic viruses as engineering platforms for combination immunotherapy
inferred← citeshttps://doi.org/10.1038/s41577-018-0014-6openalex-snapshot
Integrating oncolytic viruses in combination cancer immunotherapy
inferred← citeshttps://doi.org/10.1073/pnas.2618249123openalex-snapshot
MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1080/02648725.2018.1474320openalex-snapshot
Rhabdoviruses as vaccine platforms for infectious disease and cancer
inferred← citeshttps://doi.org/10.1080/14712598.2020.1729351openalex-snapshot
Combination therapy with oncolytic viruses and immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1080/1750743x.2025.2513853openalex-snapshot
Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack
inferred← citeshttps://doi.org/10.1080/2162402x.2018.1503032openalex-snapshot
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors
inferred← citeshttps://doi.org/10.1089/hum.2021.048openalex-snapshot
Antifibrotic Therapy Augments the Antitumor Effects of Vesicular Stomatitis Virus Via Reprogramming Tumor Microenvironment
inferred← citeshttps://doi.org/10.1099/jgv.0.000980openalex-snapshot
Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update
inferred← citeshttps://doi.org/10.1136/jitc-2020-000763openalex-snapshot
Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
inferred← citeshttps://doi.org/10.1136/jitc-2020-001387openalex-snapshot
In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
inferred← citeshttps://doi.org/10.1136/jitc-2022-006518openalex-snapshot
Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-18-1932openalex-snapshot
Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-19-2078openalex-snapshot
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
inferred← citeshttps://doi.org/10.1172/jci122287openalex-snapshot
Oncolytic viruses: overcoming translational challenges
inferred← citeshttps://doi.org/10.1172/jci98047openalex-snapshot
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
inferred← citeshttps://doi.org/10.1182/bloodadvances.2018025593openalex-snapshot
Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model
inferred← citeshttps://doi.org/10.1186/s12935-022-02846-xopenalex-snapshot
Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
inferred← citeshttps://doi.org/10.1186/s12943-020-01275-6openalex-snapshot
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
inferred← citeshttps://doi.org/10.1186/s12943-021-01346-2openalex-snapshot
Delivery of cancer therapies by synthetic and bio-inspired nanovectors
inferred← citeshttps://doi.org/10.1200/po.20.00395openalex-snapshot
Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice
inferred← citeshttps://doi.org/10.18632/oncotarget.25614openalex-snapshot
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2251036/v1openalex-snapshot
Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer
inferred← citeshttps://doi.org/10.2147/ov.s143808openalex-snapshot
Current understanding of reovirus oncolysis mechanisms
inferred← citeshttps://doi.org/10.2147/ov.s145532openalex-snapshot
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
inferred← citeshttps://doi.org/10.30466/vrf.2022.542258.3297openalex-snapshot
Apoptotic activity of Newcastle disease virus in comparison with nisin A in MDA-MB-231 cell line.
inferred← citeshttps://doi.org/10.3389/fimmu.2017.00555openalex-snapshot
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives
inferred← citeshttps://doi.org/10.3389/fimmu.2018.00866openalex-snapshot
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2019.01848openalex-snapshot
Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study
inferred← citeshttps://doi.org/10.3389/fimmu.2020.00683openalex-snapshot
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment
inferred← citeshttps://doi.org/10.3389/fimmu.2021.754436openalex-snapshot
Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1308890openalex-snapshot
Oncolytic virotherapy in cancer treatment: challenges and optimization prospects
inferred← citeshttps://doi.org/10.3390/biomedicines7030066openalex-snapshot
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
inferred← citeshttps://doi.org/10.3390/cancers10060205openalex-snapshot
Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
inferred← citeshttps://doi.org/10.3390/cancers12113219openalex-snapshot
Past, Present and Future of Oncolytic Reovirus
inferred← citeshttps://doi.org/10.3390/cancers12113354openalex-snapshot
Oncolytic Adenovirus in Cancer Immunotherapy
inferred← citeshttps://doi.org/10.3390/cancers12123552openalex-snapshot
Newcastle Disease Virus at the Forefront of Cancer Immunotherapy
inferred← citeshttps://doi.org/10.3390/cells15050393openalex-snapshot
Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation
inferred← citeshttps://doi.org/10.3390/ijms21145130openalex-snapshot
Self-Amplifying RNA Viruses as RNA Vaccines
inferred← citeshttps://doi.org/10.3390/ijms21207505openalex-snapshot
Clinical Application of Oncolytic Viruses: A Systematic Review
inferred← citeshttps://doi.org/10.3390/v10080421openalex-snapshot
Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection
inferred← citeshttps://doi.org/10.34238/tnu-jst.6502openalex-snapshot
ĐẶC ĐIỂM SINH HỌC VÀ CHIẾN LƯỢC TĂNG HOẠT ĐỘNG CỦA ADENOVIRUS ĐỂ GÂY TAN TẾ BÀO UNG THƯ
inferred← citeshttps://doi.org/10.5772/intechopen.100183openalex-snapshot
Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing
inferred← citeshttps://doi.org/10.6084/m9.figshare.13219295openalex-snapshot
Additional file 1 of Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
inferred← citeshttps://doi.org/10.70675/6b8b8b92zda75z46a0z98e6zc9f888cb9715openalex-snapshot
T immune responses to SARS-CoV-2 : identification of the immunogenic region associated with protection against infection
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.